Drugs / tipifarnib
Trials 88 · started per year
today
1
3
10
9
14
7
11
6
6
5
1
1
2
2
2
1
1
1
2
1
1
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
News releases announcing trial results or a regulatory action · 30
| Date | Issuer | Release |
|---|---|---|
| 2025-10-18 | Kura Oncology, Inc. | Results Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress kuraoncology.com ↗
Robust antitumor activity was observed in heavily pretreated patients with relapsed or metastatic HNSCC with PIK3CA alterations |
| 2023-10-17 | Kura Oncology, Inc. | Results Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC kuraoncology.com ↗
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced results from its registration-directed AIM-HN study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease is recurrent or metastatic and has progressed after prior therapy. |
| 2023-04-17 | Kura Oncology, Inc. | Results Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies kuraoncology.com ↗
These data support the potential to administer an FTI in combination with a TKI for the treatment of RCC, and studies are ongoing to further evaluate the mechanistic basis of the synergy observed with the combination. |
| 2022-10-26 | Kura Oncology, Inc. | Results Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma kuraoncology.com ↗
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported proof of mechanism in KURRENT-HN, the Company’s Phase 1/2 clinical trial of tipifarnib in combination with alpelisib in patients with HRAS- and/or PIK3CA-dependent head and neck squamous cell carcinoma (HNSCC). |
| 2021-12-13 | Kura Oncology, Inc. | Results Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma kuraoncology.com ↗ |
| 2021-03-22 | Kura Oncology, Inc. | Results Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology kuraoncology.com ↗
Median progression-free survival (PFS) of 5.6 months (95% CI, 3.6 to 16.4) on tipifarnib was a statistically significant improvement over the median PFS of 3.6 months (95% CI, 1.3 to 5.2) on last prior therapy (p=0.0012). |
| 2021-02-24 | Kura Oncology, Inc. | Regulatory Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma kuraoncology.com ↗ |
| 2020-10-26 | Kura Oncology, Inc. | Results Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Kα Inhibitor in Head and Neck Squamous Cell Carcinoma kuraoncology.com ↗ |
| 2020-05-29 | Kura Oncology, Inc. | Results Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma kuraoncology.com ↗
Median overall survival (OS) was 15.4 months (95% CI, 7.0 to 46.4). |
| 2020-03-03 | Kura Oncology, Inc. | Regulatory Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas kuraoncology.com ↗
the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib |
| 2019-12-16 | Kura Oncology, Inc. | Regulatory Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial kuraoncology.com ↗
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of patients with HRAS mutant head and neck squamous cell carcinomas (HNSCC) after progression on platinum therapy. |
| 2019-12-08 | Kura Oncology, Inc. | Results Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma kuraoncology.com ↗
Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma |
| 2019-10-29 | Kura Oncology, Inc. | Results Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer kuraoncology.com ↗
Ten of the 18 evaluable patients achieved a confirmed partial response (PR), as defined by standard RECIST criteria, for an objective response rate ( ORR ) of 56% (95% CI 0.31, 0.78). |
| 2019-09-03 | Kura Oncology, Inc. | Results Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma kuraoncology.com ↗ |
| 2019-06-14 | Kura Oncology, Inc. | Results Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma kuraoncology.com ↗
PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an ORR of 47% and a clinical benefit rate of 82% |
| 2019-04-02 | Kura Oncology, Inc. | Results Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications kuraoncology.com ↗
Pre-treatment tumor CXCL12 expression identified as a potential biomarker of clinical benefit in patients with DLBCL and CTCL |
| 2019-01-18 | Kura Oncology, Inc. | Results Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression kuraoncology.com ↗
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported new findings identifying a potential association between CXCL12 expression and clinical benefit in patients with pancreatic cancer treated with tipifarnib. |
| 2018-12-02 | Kura Oncology, Inc. | Results Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma kuraoncology.com ↗
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported preliminary data in angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ peripheral T-cell lymphoma (PTCL), the two expansion cohorts in its Phase 2 clinical trial of its lead drug candidate tipifarnib in patients with relapsed or refractory PTCL. |
| 2018-10-22 | Kura Oncology, Inc. | Results Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC kuraoncology.com ↗
Tumor size reductions were observed in nine of 11 evaluable patients, with five confirmed partial responses (PRs) as defined by standard RECIST criteria, including three patients with durable responses lasting more than 17 months. |
| 2018-02-15 | Kura Oncology, Inc. | Results Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer kuraoncology.com ↗
Five out of the six evaluable patients achieved a confirmed, partial response as defined by standard RECIST criteria for an overall response rate of 83% (36-99.6%, 95%CI), including durable responses of more than 18 months in two patients. |
| 2017-12-11 | Kura Oncology, Inc. | Results Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers kuraoncology.com ↗ |
| 2017-12-10 | Kura Oncology, Inc. | Results Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia kuraoncology.com ↗
Kura Oncology, Inc. , (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported positive, preliminary results from a Phase 2 clinical study of its lead candidate tipifarnib in patients with chronic myelomonocytic leukemia (CMML). |
| 2017-10-27 | Kura Oncology, Inc. | Results Kura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update kuraoncology.com ↗
Four out of six evaluable HRAS mutant HNSCC patients enrolled in the study achieved a confirmed partial response, as defined by standard RECIST criteria. |
| 2017-09-07 | Kura Oncology, Inc. | Results Kura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer kuraoncology.com ↗ |
| 2017-08-07 | Kura Oncology, Inc. | Results Kura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 Study kuraoncology.com ↗
Furthermore, the durability of response – beyond one year in two patients – has been impressive, particularly when considering these patients received limited clinical benefit from prior therapy before enrolling in the study. |
| 2017-06-14 | Kura Oncology, Inc. | Results Kura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma kuraoncology.com ↗
The preliminary results of this study are exciting because they may define a molecular mechanism of action and characterize a subgroup of patients that derive significantly greater clinical benefit from a targeted therapy such as tipifarnib. |
| 2017-03-06 | Kura Oncology, Inc. | Results Kura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for Tipifarnib kuraoncology.com ↗
Among the five patients with HRAS mutant salivary gland cancer, although no objective responses were observed, three patients experienced disease stabilization and were on study for 9, 10 and 14 cycles. |
| 2016-11-04 | Kura Oncology, Inc. | Results Kura Oncology Presents Update on Pipeline Programs Targeting RAS-ERK Pathway at European Scientific Oncology Conference kuraoncology.com ↗
Two of the three SCCHN patients experienced a confirmed partial response (PR) and have been on study for 15 months and 8 months, while a third patient experienced disease stabilization for 7 months. |
| 2016-08-10 | Kura Oncology, Inc. | Results Kura Oncology Reports Second Quarter 2016 Financial Results kuraoncology.com ↗
In the company’s Phase 2 trial of tipifarnib in HRAS mutant solid tumors, positive clinical activity, including objective responses, has been observed in patients with head and neck squamous cell carcinomas and patients with salivary gland cancer. |
| 2015-12-03 | Kura Oncology, Inc. | Results Kura Oncology Announces Data Presentation on Lead Product Candidate Tipifarnib at the Upcoming ASH Meeting kuraoncology.com ↗
Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. |
All press releases naming this drug 49 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 96 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tipifarnib | “gemcitabine with and without tipifarnib (referred to as R115777).” NCT00005648 ↗ |
| Known as | NSC #70818 | “Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal” PMID 16683076 ↗ Jul 2006 |
| Known as | NSC-702818 | “Phase II Trial of R115777 (NSC-702818), an Inhibitor of Farnesyl Protein Transferase, in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma” NCT00005843 ↗1“Phase I/II Study of Tipifarnib [Zarnestra, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders” NCT02210858 ↗ |
| Known as | R11577 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00361088 ↗ |
| Known as | R115777 | “Tipifarnib (R115777) inhibits farnesylation of key proteins that modulate signaling pathways implicated in cell growth and proliferation, including members of the Ras and Rho families.” PMID 15711184 ↗ Mar 200516“Phase II Trial of R115777 (NSC-702818), an Inhibitor of Farnesyl Protein Transferase, in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma” NCT00005843 ↗ “Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.” PMID 21725056 ↗ Jul 2011 “A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder” NCT00047216 ↗ “Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with” PMID 15570084 ↗ Dec 2004 “Patients receive oral R115777 twice daily on days 1-21.” NCT00012350 ↗ “ZARNESTRA, tipifarnib, R115777” NCT00050141 ↗ “ZARNESTRA, tipifarnib, R115777” NCT00050154 ↗ “ZARNESTRA, tipifarnib, R115777” NCT00048503 ↗ “Tipifarnib;Zarnestra; R115777” NCT00093990 ↗ “tipifarnib (R115777)” NCT00354146 ↗ |
| Known as | R15777 | “A Phase II Trial Of Tipifarnib (R15777, ZARNESTRA) In Combination With Tamoxifen In Subjects With Metastatic Breast Cancer” NCT00052728 ↗ |
| Known as | ZARNESTRA | “A Phase II Trial Of Tipifarnib (R15777, ZARNESTRA) In Combination With Tamoxifen In Subjects With Metastatic Breast Cancer” NCT00052728 ↗10“A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder” NCT00047216 ↗ “tipifarnib (ZARNESTRA) treatment” NCT01361464 ↗ “ZARNESTRA, tipifarnib, R115777” NCT00050154 ↗ “ZARNESTRA, tipifarnib, R115777” NCT00050141 ↗ “ZARNESTRA, tipifarnib, R115777” NCT00048503 ↗ “Tipifarnib;Zarnestra; R115777” NCT00093990 ↗ “ZARNESTRA (Tipifarnib)” NCT00847223 ↗ |
| Action | Inhibit | “R115777, an oral farnesyl transferase inhibitor” PMID 16133800 ↗ Oct 2005 |
| Modality | Small molecule | “R115777 is a selective nonpeptidomimetic inhibitor of farnesyltransferase (FTase), one of several enzymes responsible for posttranslational modification that is required for...” PMID 12663718 ↗ Apr 2003 |
| Route | Oral | “oral tipifarnib every 12 hours beginning on day 2” NCT00003707 ↗ |
| Target | HRAS | “disrupts HRAS function” PMID 33750196 ↗ Mar 2021 |